Contact
searchSearch
HMP Global

September 2011 - FRMC

Cited Studies on Biomarker Discoveries Prone to Exaggerating Effects
09/19/2011
Christin Melton
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking...
09/19/2011
First Report Managed Care
Telaprevir Improves Outcomes in Some Patients with Hepatitis C
09/19/2011
Christin Melton
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used...
09/19/2011
First Report Managed Care
Linaclotide Significantly Improves Quality of Life and Abdominal Symptoms
09/19/2011
Christin Melton
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide...
09/19/2011
First Report Managed Care
Comparing Adjuvant Chemotherapy Regimens in Non–Small-Cell Lung Cancer
09/19/2011
Tim Casey
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2...
09/19/2011
First Report Managed Care
Six-Year Follow-Up of Lenalidomide for Multiple Myeloma
09/19/2011
Tim Casey
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of...
09/19/2011
First Report Managed Care
Glucose-Lowering Effect of Insulin Degludec
09/19/2011
Tim Casey
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized,...
09/19/2011
First Report Managed Care
Cost of Comorbidities in Obese Adults
09/19/2011
Tim Casey
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from...
09/19/2011
First Report Managed Care
Pooled Analysis of Exenatide to Treat Type 2 Diabetes
09/19/2011
Tim Casey
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of...
09/19/2011
First Report Managed Care
Oral Antidiabetics for Type 2 Diabetes and Chronic Kidney Disease
09/19/2011
Tim Casey
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of...
09/19/2011
First Report Managed Care
Saxagliptin Safe, Effective after 4 Years
09/19/2011
Tim Casey
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year...
09/19/2011
First Report Managed Care
Factors Affecting Health Disparities in Diabetes Patients
09/19/2011
Tim Casey
San Diego—After analyzing electronic health records (EHRs) of patients with type 2 diabetes living in the southeast United States, researchers concluded that improving diabetes control and health equity can be achieved through focusing on...
San Diego—After analyzing electronic health records (EHRs) of patients with type 2 diabetes living in the southeast United States, researchers concluded that improving diabetes control and health equity can be achieved through focusing on...
San Diego—After analyzing...
09/19/2011
First Report Managed Care
Effect of Education, Counseling on Diabetes Care
09/19/2011
Tim Casey
San Diego—A retrospective analysis of medical insurance claims data found patients with diabetes who received education and counseling were more likely to have glycemic control and lower diabetes-related healthcare charges compared with those...
San Diego—A retrospective analysis of medical insurance claims data found patients with diabetes who received education and counseling were more likely to have glycemic control and lower diabetes-related healthcare charges compared with those...
San Diego—A retrospective...
09/19/2011
First Report Managed Care
Linagliptin to Treat Type 2 Diabetes Patients with Severe Renal Impairment
09/19/2011
Tim Casey
San Diego—In a randomized, double-blind, placebo-controlled, phase 3 trial of patients with type 2 diabetes and severe renal impairment, researchers found that those who took linagliptin for 12 weeks had a significant reduction in hemoglobin...
San Diego—In a randomized, double-blind, placebo-controlled, phase 3 trial of patients with type 2 diabetes and severe renal impairment, researchers found that those who took linagliptin for 12 weeks had a significant reduction in hemoglobin...
San Diego—In a randomized,...
09/19/2011
First Report Managed Care
Disease Stage and Liraglutide in Type 2 Diabetes
09/19/2011
Tim Casey
San Diego—A pooled analysis of 7 randomized phase 3a and 3b trials found that patients with type 2 diabetes who were treatment naïve or used liraglutide as an add-on therapy to 1 oral antidiabetic agent had a significant reduction in...
San Diego—A pooled analysis of 7 randomized phase 3a and 3b trials found that patients with type 2 diabetes who were treatment naïve or used liraglutide as an add-on therapy to 1 oral antidiabetic agent had a significant reduction in...
San Diego—A pooled analysis of 7...
09/19/2011
First Report Managed Care
More Rigorous Studies Needed to Assess Use of Advanced Access Scheduling in Primary Care
09/19/2011
Christin Melton
An analysis of published English-language studies on advanced access (AA) scheduling in the primary care setting revealed mixed results [Arch Intern Med. 2011;171(13):1150-1159]. Although wait times for an appointment typically decreased, as...
An analysis of published English-language studies on advanced access (AA) scheduling in the primary care setting revealed mixed results [Arch Intern Med. 2011;171(13):1150-1159]. Although wait times for an appointment typically decreased, as...
An analysis of published...
09/19/2011
First Report Managed Care
Spending and Quality in First Year of the Alternative Quality Contract
09/19/2011
Tori Socha
In January 2009, Blue Cross Blue Shield (BCBS) of Massachusetts implemented the Alternative Quality Contract (AQC) payment system. Based on global payment and pay for performance, AQC was implemented in response to continued growth in...
In January 2009, Blue Cross Blue Shield (BCBS) of Massachusetts implemented the Alternative Quality Contract (AQC) payment system. Based on global payment and pay for performance, AQC was implemented in response to continued growth in...
In January 2009, Blue Cross Blue...
09/19/2011
First Report Managed Care
Infections and Cost in Obese Patients Undergoing Colectomy
09/19/2011
Tori Socha
Policymakers utilize rates of surgical site infection (SSI) as a surrogate measure of quality in surgery. Beginning in 2012, hospital SSI rates will be reported to the public. Federal, state, and local pay-for-performance policies are...
Policymakers utilize rates of surgical site infection (SSI) as a surrogate measure of quality in surgery. Beginning in 2012, hospital SSI rates will be reported to the public. Federal, state, and local pay-for-performance policies are...
Policymakers utilize rates of...
09/19/2011
First Report Managed Care
Medicare Part D and Nondrug Medical Spending
09/19/2011
Tori Socha
The Medicare Part D prescription drug benefit has been associated with increased medication use, reduced expenses, and improved patient adherence rates.
The Medicare Part D prescription drug benefit has been associated with increased medication use, reduced expenses, and improved patient adherence rates.
The Medicare Part D prescription...
09/19/2011
First Report Managed Care
Diabetic Kidney Disease in the United States
09/19/2011
Tori Socha
In the developed world, diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. It is estimated that 40% of individuals with diabetes develop DKD, manifested as albuminuria, impaired glomerular filtration rate (GFR), or...
In the developed world, diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. It is estimated that 40% of individuals with diabetes develop DKD, manifested as albuminuria, impaired glomerular filtration rate (GFR), or...
In the developed world, diabetic...
09/19/2011
First Report Managed Care
Most Americans Not Familiar with Parts of ACA Designed to Improve Coverage Access
09/19/2011
The August 2011 tracking poll conducted by the Henry J. Kaiser Family Foundation focused on the opinions of Americans currently without health insurance and the ways they think the Patient Protection and Affordable Care Act (ACA) will affect...
The August 2011 tracking poll conducted by the Henry J. Kaiser Family Foundation focused on the opinions of Americans currently without health insurance and the ways they think the Patient Protection and Affordable Care Act (ACA) will affect...
The August 2011 tracking poll...
09/19/2011
First Report Managed Care
Study Examines Cost-Shifting and MedPAC Perspectives on Hospital Pricing, Profitability
09/19/2011
Tim Casey
A recent analysis of 7 common procedures found that hospitals’ contribution margins were 831% higher when treating patients covered by private health insurance compared with Medicare patients. The results also indicated that in 4 of the...
A recent analysis of 7 common procedures found that hospitals’ contribution margins were 831% higher when treating patients covered by private health insurance compared with Medicare patients. The results also indicated that in 4 of the...
A recent analysis of 7 common...
09/19/2011
First Report Managed Care
Drug Shortages Cause Concern for Healthcare Industry
09/19/2011
Tim Casey
Since 1968, Michael Cohen has worked as a pharmacist, focusing on helping patients and ensuring he is providing safe and effective therapies. Mr. Cohen is now president of the Institute for Safe Medication Practices, a nonprofit...
Since 1968, Michael Cohen has worked as a pharmacist, focusing on helping patients and ensuring he is providing safe and effective therapies. Mr. Cohen is now president of the Institute for Safe Medication Practices, a nonprofit...
Since 1968, Michael Cohen has...
09/19/2011
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

September 2011 Volume 8 Issue 9

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use